title: Plasma and cellular pharmacokinetics of mitoxantrone in high-dose chemotherapeutic regimen for refractory lymphomas.
abstract: We have studied the plasma and peripheral leukocyte pharmacokinetics of mitoxantrone associated, in a high-dose regimen, with cyclophosphamide, carmustine, and etoposide in patients with refractory lymphoma undergoing autologous bone marrow transplantation. Nineteen patients with refractory lymphoma were involved in a clinical trial with escalated doses (15-90 mg/m2) of mitoxantrone administered by 30-min i.v. infusion 8 days before an autologous bone marrow transfusion. Mitoxantrone was measured by high-performance liquid chromatography in plasma and peripheral lymphocytes. The plasma pharmacokinetics of mitoxantrone was linear between 15 and 90 mg/m2: total body clearance (19.3 +/- 6.2 liter/h/m2) and volume of distribution at steady state (486 +/- 254 liter/m2) were not altered by increasing the dose. The exposure of bone marrow transplant to the plasma residual concentration of mitoxantrone was correlated with the limiting hematological toxicity of the regimen (P < 0.001). At all times, the mitoxantrone concentration in peripheral cells was much higher than in plasma and was retained at a constantly high concentration level. Whereas cellular versus plasma maximum concentration ratio was near 1, the area under the concentration +/- time curve ratio reached 100, suggesting a long elimination half-life from cells. Plasma and cellular pharmacokinetics data of mitoxantrone reinforce the idea that this drug is a good candidate for high-dose chemotherapy regimen.
authors.affiliation: Groupe de Pharmacologie Clinique et Expérimentale des Médicaments Anticancéreux, Centre Claudius Regaud, Toulouse, France.
authors.forename: P
authors.initials: P
authors.lastname: Canal
authors.forename: M
authors.initials: M
authors.lastname: Attal
authors.forename: E
authors.initials: E
authors.lastname: Chatelut
authors.forename: S
authors.initials: S
authors.lastname: Guichard
authors.forename: F
authors.initials: F
authors.lastname: Huguet
authors.forename: C
authors.initials: C
authors.lastname: Muller
authors.forename: D
authors.initials: D
authors.lastname: Schlaifer
authors.forename: G
authors.initials: G
authors.lastname: Laurent
authors.forename: G
authors.initials: G
authors.lastname: Houin
authors.forename: R
authors.initials: R
authors.lastname: Bugat
mesh_terms: D000328:Adult; D004305:Dose-Response Relationship, Drug; D006689:Hodgkin Disease / Q000188:drug therapy; D006801:Humans; D008223:Lymphoma / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D008942:Mitoxantrone / Q000097:blood / Q000493:pharmacokinetics* / Q000633:toxicity*
chemical_list: D008942:Mitoxantrone